Blackstone Life Sciences and Novartis Launch Anthos Therapeutics to Develop Cardiovascular Disease Treatments

Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients.